What is Compound A in Sevoflurane?
Compound A is pentafluoroisopropenyl fluoromethyl ether (PIFE, C₄H₂F₆O), a fluorinated degradation product formed when sevoflurane reacts with alkaline carbon dioxide absorbents (particularly Baralyme and soda lime) in the anesthesia circuit. 1
Chemical Formation and Mechanism
Compound A forms through a defluorination pathway when sevoflurane contacts strong bases (KOH and/or NaOH) in CO₂ absorbents. The reaction extracts an acidic proton from sevoflurane, creating this alkene degradation product—similar to how halothane forms BCDFE 1. This is the first of two degradation pathways for sevoflurane, with the second pathway (occurring primarily with desiccated absorbents) producing hexafluoroisopropanol and formaldehyde 1.
Factors Increasing Compound A Production
Compound A concentration increases with:
- Lower fresh gas flow rates (inversely correlated) 1, 2
- Desiccated CO₂ absorbents, especially those containing potassium hydroxide like Baralyme 1, 2
- Higher absorbent temperatures (from exothermic CO₂ absorption) 1
- Higher sevoflurane concentrations 1
- Longer anesthesia duration 1
- Baralyme versus soda lime (Baralyme produces higher levels) 1, 2
Clinical Concentrations
At fresh gas flow rates of 1 L/min, mean maximum Compound A concentrations in clinical settings are approximately:
- 20 ppm with soda lime in adults
- 30 ppm with Baralyme in adults
- Half these levels in pediatric patients 1
The highest single-patient concentration observed was 61 ppm with Baralyme and 32 ppm with soda lime 1.
Toxicity Profile
Animal data: Compound A demonstrates nephrotoxicity in rats, causing proximal tubular necrosis. The LC₅₀ at 1 hour is 1050-1090 ppm, and at 3 hours is 350-490 ppm. Sporadic single-cell necrosis occurred at 114 ppm after 3-hour exposure 1. In cynomolgus monkeys, an 8-hour exposure to sevoflurane with 75-100 ppm Compound A produced single-cell renal tubular degeneration and necrosis 1.
Human relevance: The concentration at which Compound A causes toxicity in humans remains unknown 1. The mechanism involves metabolism through the renal cysteine conjugate β-lyase pathway, which is 10- to 30-fold less active in humans than in rats 3, 4. This suggests humans may be substantially less susceptible to Compound A nephrotoxicity.
Clinical Evidence in Humans
Studies examining renal effects in surgical patients and volunteers using both standard markers (creatinine clearance, BUN, serum creatinine) and experimental markers (urinary protein, glucose, NAG, GST, AAP) have shown:
- No case reports of Compound A-associated renal injury in humans 4
- Some volunteer studies found transient changes in experimental but not conventional renal markers 3, 4
- Recent data (2025) showed no acute kidney injury with sevoflurane-based low-flow anesthesia at 600-1000 mL/min for surgeries lasting 120-780 minutes 5
Practical Mitigation Strategies
To minimize Compound A exposure:
- Use fresh CO₂ absorbents (avoid desiccated absorbents) 1
- Maintain adequate fresh gas flow rates (≥1 L/min for exposures up to 1 hour; ≥2 L/min for exposures >1 hour per FDA recommendations) 3
- Avoid absorbents containing potassium hydroxide (Baralyme is no longer commercially available) 1
- Consider absorbents free of strong bases (Loflosorb, Superia produce no Compound A or CO) 2
- Circuit cooling can reduce Compound A concentrations (from 27.1 ppm to 16.3 ppm in one study) 6
The FDA's cautious approach recommends flow rate limitations, though other countries have not imposed such restrictions without reported problems 3. Current evidence suggests sevoflurane is safe when used according to manufacturer guidelines with fresh absorbents, as degradation is minimal and degradants are either undetectable or present in non-toxic amounts 1.